Abstract
Case summary
A 35-year-old man was diagnosed with hypoxic brain damage caused by ventricular fibrillation. The patient showed Parkinsonism and was started on treatment with amantadine. Thirty-seven months after the commencement of amantadine treatment, the patient suffered a corneal ulcer in his right eye, which healed with opacity and thinning after medical treatment. After healing, slit-lamp examination revealed a bilateral, epithelial and stromal edema without obvious guttae and keratic precipitates. The corneal edema did not improve with topical treatment of 5% NaCl and 0.02% fluorometholone in both eyes. Three months after leaving the hospital, the patient's corrected visual acuity decreased to 0.2 (−2.0 Dsph −0.5 Dcyl Ax 90) in the right eye and 0.4 (−0.75 Dsph −2.0 Dcyl Ax 90) in the left eye. Amantadine medication was discontinued after discussion with the patient's neurologist. At the 1-month follow-up, corneal examination revealed resolution of the epithelial and stromal edema in both eyes. Corrected visual acuity was improved to 0.5 (−1.5 Dsph) in the right eye and 0.7 (−1.0 Dsph −1.0 Dcyl Ax 90) in the left eye.
References
1. Offret H, Labetoulle M, Offret O. Corneal edema and systemic NSAIDS. J Fr Ophthalmol. 2007; 30:e14.
2. Platt LW. Bilateral peripheral corneal edema after cefaclor therapy. Arch Ophthalmol. 1990; 108:175.
3. Oshika T, Itotagawa K, Sawa M. Severe corneal edema after prolonged use of psychotropic agents. Cornea. 1991; 10:354–7.
4. Fraunfelder FT, Fraunfelder FW. Drug-induced ocular side effects. 5th ed.Boston: Butterworth-Heinemann;2001. p. 421–2.
6. Amantadine. Physician's Desk References. 57th ed.Montvale, NJ: Thompson healthcare;2003. p. 1213–5.
7. Hughes B, Feiz V, Flynn SB, Brodsky MC. Reversible amantadine-induced corneal edema in adolescent. Cornea. 2004; 23:823–4.
8. Kubo SI, Iwatake A, Ebihara N, et al. Visual impairment in Parkinson's disease treated with amantadine: case report and review of the literature. Parkinsonism Relat Disord. 2007; 14:166–9.
9. Jeng BH, Galor A, Lee MS, et al. Amantadine-associated corneal edema potentially irreversible even after cessation of the medication. Ophthalmology. 2008; 115:1540–4.
10. French DD, Margo CE. Postmarketing surveillance of corneal edema, Fuchs dystrophy, and amantadine use in the Veterans Health Administration. Cornea. 2007; 26:1087–9.
11. Kornhuber J, Weller M, Schoppmeyer K, et al. Amantadine and memantine are NMDA receptor antagonist with neuroprotective properties. J Neural Transm Supple. 1994; 43:91–104.
13. Chang KC, Kim MK, Wee WR, Lee JH. Corneal endothelial dysfunction associated with amantadine toxicity. Cornea. 2008; 27:1182–85.
14. Schwab RS, England Jr AC, Poskanzer DC, Young RR. Amantadine in the treatment of Parkinson's disease. JAMA. 1969; 208:1168–70.
15. Krachmer JH, Mannis MJ, Holland EJ. Cornea. 2nd ed. 1. Philadelphia: Elsevier Inc.;2005. p. 360.
16. Waring GO Ⅲ. Posterior collagenous layer of the cornea: ultrastructural classification of abnormal collagenous tissue posterior to Descemet's membrane in 30 cases. Arch Ophthalmol. 1982; 100:122–34.